Measuring tumor-specific genetic alterations in cerebrospinal fluid (CSF) as a biomarker of tumor burden in malignant brain tumor patients. - Not applicable

Johns Hopkins University School of Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Age >18 years for Cohort 1: patients with suspected or confirmed malignant brain tumor who are eligible for surgical resection, chemotherapy or radiation treatments, as identified by the site PI or Co-Is through routine clinical care processes
•2. Age >12 years for Cohort 2: patients, including children, with malignant brain tumor, who are undergoing a diagnostic or therapeutic lumbar puncture, as identified by the site PI or Co-Is through routine clinical care processes
•3. Life expectancy of greater than 6 months
•4. Patients must have normal lab criteria as defined below:
•4a) Platelets >= 100,000/mcL
•4b) PTT above institutional limits
•4c) INR above institutional limits
•5) Ability to understand and the willingness to sign a written Informed Consent Form for patients >18 years and an Assent form for patients <18 years
•6) Both men and women of all races and ethnic groups are eligible for this study

•1) Patients who have an uncontrolled infection
•2) Patients who are receiving an investigational agent(s) that increases the risks associated with cerebrospinal fluid sampling
•3) Patients with clinical or radiographic evidence of elevated intracranial pressure (such as papilledema, obstructive hydrocephalus, or signs of herniation)
•4) Patients who are coagulopathic and are taking blood thinning products, such as plavix, lovenox, or coumadin. Patients maybe on steroids or anti-convulsant therapy without affecting eligibility
•5) Women who are pregnant or suspect they are pregnant or lactating mothers

发起方